The signal pathways and treatment of cytokine storm in COVID-19
L Yang, X Xie, Z Tu, J Fu, D Xu, Y Zhou - Signal transduction and …, 2021 - nature.com
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …
and is more devastating than any other previous infectious disease. It has affected a …
SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders
SARS-CoV-2 is a novel coronavirus that severely affects the respiratory system, is the cause
of the COVID-19 pandemic, and is projected to result in the deaths of 2 million people …
of the COVID-19 pandemic, and is projected to result in the deaths of 2 million people …
Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19
RS Thwaites, A Sanchez Sevilla Uruchurtu… - Science …, 2021 - science.org
While it is now widely accepted that host inflammatory responses contribute to lung injury,
the pathways that drive severity and distinguish coronavirus disease 2019 (COVID-19) from …
the pathways that drive severity and distinguish coronavirus disease 2019 (COVID-19) from …
Clonal expansion and activation of tissue-resident memory-like TH17 cells expressing GM-CSF in the lungs of patients with severe COVID-19
Hyperinflammation contributes to lung injury and subsequent acute respiratory distress
syndrome with high mortality in patients with severe coronavirus disease 2019 (COVID-19) …
syndrome with high mortality in patients with severe coronavirus disease 2019 (COVID-19) …
A global picture: therapeutic perspectives for COVID-19
VP Chavda, C Kapadia, S Soni, R Prajapati… - …, 2022 - Taylor & Francis
The COVID-19 pandemic is a lethal virus outbreak by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), which has severely affected human lives and the global …
coronavirus-2 (SARS-CoV-2), which has severely affected human lives and the global …
[HTML][HTML] COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
SARS-CoV-2 is the virus responsible for the COVID-19 pandemic. COVID-19 has highly
variable disease severity and a bimodal course characterized by acute respiratory viral …
variable disease severity and a bimodal course characterized by acute respiratory viral …
An overview on the treatments and prevention against COVID-19
Y Panahi, AM Gorabi, S Talaei, F Beiraghdar… - Virology Journal, 2023 - Springer
Background The coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While …
respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While …
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
Z Temesgen, CD Burger, J Baker, C Polk… - The Lancet …, 2022 - thelancet.com
Background The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Abstract The coronavirus disease 2019 (COVID-19) pandemic is an exceptional public
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open …
Background Dysregulated inflammation is associated with poor outcomes in COVID-19. We
aimed to assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating …
aimed to assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating …